HDT Bio’s RNA-based vaccine offers simpler manufacturing, easier deployment without the need for ultra-low freezers, and requires vastly lower dosing than current RNA COVID-19 vaccines SEATTLE & SALVADOR, Brazil--January 17, 2022--HDT Bio Corp., a U.S. developer...

HDT’s RNA-based vaccine offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines  Quratis could make vaccine available across East Asia Seattle, WA, and Seoul, KOREA (December 13, 2021) – HDT Bio Corp., a...

Agreement extends HDT Bio’s international COVID 19 vaccine partnerships as part of its long-term goal of changing the global-health paradigm to address global-health inequity The company’s RNA-based vaccine offers simpler manufacturing, easier deployment without the...